Advanced Filters
noise

Sirolimus Clinical Trials

A listing of Sirolimus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 60 clinical trials
A Anabela M Cieslicki

Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

The objective of this study is to explore the effects of Sirolimus on the underlying molecular alterations of cerebral aneurysms.

18 years of age All Phase 2
U Uday Popat

A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease

The goal of this clinical research study is to compare the effects of these drug combinations (cyclophosphamide, sirolimus, and MMF vs cyclophosphamide, sirolimus, and ruxolitinib) on the prevention of GVHD after a stem cell transplant.

65 - 75 years of age All Phase 2
N Natalie Massenburg

Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease

The objective of this prospective, single-blinded, randomized controlled trial is to evaluate the safety and efficacy of the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions. Approximately 276 subjects will be randomized in a 1:1 ratio. The clinical investigation will be conducted at up to 60 clinical …

18 years of age All Phase N/A
i iman ahmed ragab

Systematic Approach for Children With Orbital Malformation With Sirolimus Use

The goal of this interventional study is to Set a systematic management approach for orbital lymphatic malformation and to study the safety and efficacy of sirolimus in children and adolescents with orbital lymphatic malformation\]. The main questions it aims to answer are: \[what is the safety of using sirolimus in …

1 - 18 years of age All Phase 3
J Jenn Cornelius-Green

Short Term Sirolimus Treatment and MRI of the Brain and Lungs

Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure. Sirolimus is an FDA-approved medication which may improve the blood flow to the brain. Part I: This study …

45 - 65 years of age All Phase 1
Y Yi Ji, MD

Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma

The purpose of this study is to compare the efficacy and safety of different doses of sirolimus in the maintenance treatment of kaposiform hemangioendothelioma.

- 14 years of age All Phase 2
M Molly S Griffith, BA

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants. This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and …

1 - 6 years of age All Phase 2
K Kai Li, MD, PhD

Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies

In this study, we investigate the safety and efficacy of topical sirolimus in the treatment of superficial complicated vascular anomolies.

- 18 years of age All Phase 4

SirolimUs CoaTed Balloon for The TrEatment of Below The Knee Arterial Disease

This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of below the knee arterial disease.

21 years of age All Phase N/A
J Jorge Sanz Sanchez, MD, PhD

Cutting Balloon Predilation Prior to Abluminus Sirolimus-eluting Stent Implantation (CUT-DRESS).

Drug-eluting stents iterations has significantly improved the results of percutaneous revascularization among patients undergoing coronary revascularization thanks to thinner struts, more biocompatible polymer coatings and new drug release formulations; leading to lower thrombogenicity, faster reendothelialization and improved clinical outcomes. Notwithstanding, stent-related events yet occur. Lesion pre-dilation prior to DES implantation …

18 - 99 years of age All Phase N/A

Simplify language using AI